ABEO - NASDAQ
Abeona Therapeutics Inc.
$5.82
+2.3%Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
At a Glance
Live Snapshotabeo
Stock Based Compensation
Last Annual Value
10.78M
3-Year CAGR
52%
5-Year CAGR
6%
10-Year CAGR
9%
Abeona Therapeutics Inc. Competitors Analysis of Stock Based Compensation
| Company | Stock Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Abeona Therapeutics Inc. NASDAQ:ABEO | 10.78M | 31.2% | 3.9% | 8.4% | |
 Assembly Biosciences, Inc. NASDAQ:ASMB | 4.68M | -3.0% | -2.2% | -0.7% | |
 Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT | 25.41M | -9.8% | -2.6% | 26.1% | |
 Allogene Therapeutics, Inc. NASDAQ:ALLO | 37.64M | -17.0% | -14.2% | N/A | |
 Cabaletta Bio, Inc. NASDAQ:CABA | 20.94M | 22.7% | 29.3% | N/A | |
 Kyverna Therapeutics, Inc. NASDAQ:KYTX | 10.08M | 65.6% | 6.8% | N/A | |
 Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO | 12.13M | 58.6% | 99.3% | N/A | |
 Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | 29.88M | 20.1% | 47.5% | N/A | |
 Omeros Corporation NASDAQ:OMER | 8.19M | -11.1% | N/A | -4.9% | |
 Eledon Pharmaceuticals, Inc. NASDAQ:ELDN | 10.45M | 16.9% | 5.7% | 13.3% | |
 Sagimet Biosciences Inc. NASDAQ:SGMT | 6.45M | 8.9% | 27.6% | N/A |
Abeona Therapeutics Inc. Fair Value Envelope
Related Guides
Continue your ABEO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.